A blue rectangular box labeled "ADHD Genomic" with playful graphics, white clouds, and colorful arrows on a light background. The box hints at personalized ADHD treatment and displays the website plus social media icons on the side.

Comprehensive Plus STD Panel

$70.00
Skip to product information
A blue rectangular box labeled "ADHD Genomic" with playful graphics, white clouds, and colorful arrows on a light background. The box hints at personalized ADHD treatment and displays the website plus social media icons on the side.
Comprehensive Plus STD Panel

Comprehensive Plus STD Panel

$70.00

The Comprehensive Plus STD Panel offers expanded precision testing for individuals seeking deeper clarity beyond routine screening.
 
 By identifying less common organisms with sex-specific clinical relevance, this panel supports a more complete understanding of sexual health and may help explain ongoing symptoms or concerns—empowering more informed conversations and personalized next steps.

Key Benefits

  • Screens for Mycoplasma genitalium (MG), Mycoplasma hominis (MH), Ureaplasma parvum/urealyticum (UP/UU), 
    Haemophilus ducreyi (HD), and Gardnerella vaginalis (GV)
  • Uses vaginal swab (female) or urine (male) collection
  • Includes organisms with sex-specific clinical relevance for more complete insight
  • Designed to complement routine STD screening with expanded precision
EMPTY DOM REMOVE PROTECTOR
...
......
...
Screens for Chlamydia (CT), Gonorrhea (NG), Trichomonas (TV), and HIV 1/2
Uses two sample types for accurate analysis: finger-prick blood sample and vaginal swab (female) or urine (male)
Supports routine sexual health screening and proactive monitoring
Discreet, confidential testing with lab-grade analysis

This panel screens for Chlamydia (CT), Gonorrhea (NG), Trichomonas (TV), and HIV 1/2 using two sample types for accurate, complete coverage.

A finger-prick blood sample is used for HIV antibody detection. A vaginal swab (female) or urine sample (male) is used to detect the bacterial and protozoan infections. This dual-collection approach achieves the sensitivity and specificity required to reliably detect all four pathogens.

Comprehensive protection starts with clarity. This panel screens for the most common sexually transmitted infections to support routine sexual health monitoring and peace of mind. Whether you're testing after new exposure or maintaining proactive care, this panel delivers accurate, private results you can trust.

Chlamydia & Gonorrhea

CT & NG — bacterial

Trichomonas

TV — protozoan

HIV 1/2

Viral — finger-prick

Dual sample

Blood + swab or urine

Dual Sample Collection
1
Order Your Kit—Delivered right to your door.
2
Download the App—Register your kit with the Boomerang Kits App.
3
Collect Blood Sample—Use the lancet for a quick finger-prick blood sample.
4
Dab the Card—Place drops of blood onto the collection card.
5
Collect Second Sample—Vaginal swab (female) or urine sample (male).
6
Return Mailer—Place all samples in the prepaid envelope and drop it in the mail.
7
Get Results—View secure results in the app within 24–48 hours after our lab receives your samples.
Is this test right for me?
  • You are sexually active and want routine STI screening as part of proactive sexual health care (CDC STI Treatment Guidelines 2021 — annual screening for CT, NG, and HIV is recommended for all sexually active adults.)
  • You have had a new sexual partner or multiple partners and want to confirm your status (CDC — testing after new or multiple partners is a core STI prevention recommendation.)
  • You want to screen before beginning a new relationship (USPSTF — routine screening is recommended regardless of symptoms; most STIs are asymptomatic.)
  • You have experienced symptoms such as unusual discharge, burning, or discomfort (CDC STI Guidelines — symptomatic individuals should be tested for CT, NG, TV, and HIV as a standard panel.)
  • CDC guidelines recommend annual STI screening for all sexually active adults — this panel covers the four most common infections in a single kit (CDC STI Treatment Guidelines 2021 — CT, NG, TV, and HIV are among the most prevalent STIs in the US.)
  • You want confidential testing without a clinic visit or physician referral (USPSTF HIV Screening Recommendation 2019 — supports accessible, confidential testing options for all adults.)
  • You tested positive for an STI previously and are retesting after treatment (recommended at 3 months) (CDC — test of cure at 3 months post-treatment is recommended for CT and NG due to high reinfection rates.)
What You're Testing

Key Benefits

Comprehensive STD Panel · CLIA-certified Lab · Confidential results

Panel 01 / STD CLIA-certified Lab
Chlamydia (CT)Gonorrhea (NG)Trichomonas (TV)HIV-1/2Bacterial STIViral STI
Comprehensive Sexual Health Screening
Get a clear snapshot of your sexual health with lab-grade screening for key sexually transmitted infections. This panel screens for chlamydia and gonorrhea (CT/NG), trichomonas (TV), and HIV-1/2—organizing essential results in one place to support awareness, baseline reference, and confident personal record-keeping, all from home.
Research Evidence
The CDC estimates nearly 20 million new STIs occur in the US every year — chlamydia and gonorrhea are the most frequently reported bacterial STIs and are known as silent infections because most infected people are asymptomatic
CDC guidelines recommend annual screening for chlamydia and gonorrhea in sexually active women under 25 and individuals with new or multiple partners — regardless of symptoms
STIs are biological markers of HIV acquisition risk — combined STI and HIV screening is an essential but underused component of routine sexual health care
Research Basis
Chlamydia and gonorrhea infections are frequently asymptomatic in both males and females. The CDC estimates 2.86 million chlamydia infections annually, with fewer than half reported — primarily because most people are asymptomatic and do not seek testing without a clear prompt.
CDC STI Treatment Guidelines · USPSTF Chlamydia/Gonorrhea Screening · ClinicalTrials NCT03596151
Panel 02 / STD Dual Sample
Bacterial CoverageProtozoan CoverageViral CoverageMulti-CategoryCo-Infection Screen
All-in-One Infection Coverage
This panel brings together screening across multiple infection categories in a single test—covering bacterial (chlamydia, gonorrhea), protozoan (trichomonas), and viral (HIV-1/2) markers. Results are organized clearly to support a broader view of sexual health screening without requiring multiple separate tests.
Research Evidence
Chlamydia and gonorrhea infections frequently co-exist — the USPSTF recommends screening for both simultaneously due to overlapping risk factors and the clinical benefit of combined detection
Persons diagnosed with chlamydia, gonorrhea, or trichomoniasis should be screened for HIV and retested in three months — making combined multi-pathogen screening the standard follow-up protocol
Annual trichomoniasis screening is recommended for sexually active HIV-positive women — CDC guidelines recommend opt-out screening for high-risk asymptomatic individuals at clinical intake
Research Basis
Risk factors for chlamydia and gonorrhea infection overlap significantly — the USPSTF recommends screening for both simultaneously. Patients diagnosed with any bacterial STI should also be screened for HIV and other STIs based on community prevalence and individual risk factors.
USPSTF Chlamydia/Gonorrhea Screening · AAFP CDC STI Guidelines · CDC STI Risk Assessment Guidelines
Panel 03 / STD Confidential
Dual Sample TypeFinger-Prick BloodVaginal SwabUrine CollectionSingle Report
Dual Collection for Accuracy
This panel uses a combination of sample types to support comprehensive screening. A simple finger-prick blood sample is paired with a swab or urine collection, allowing key results to be reviewed together in a single, streamlined report—without added complexity.
Research Evidence
Nucleic acid amplification testing (NAAT) using swab and urine samples is the clinical gold standard for detecting chlamydia, gonorrhea, and trichomonas — the same methodology used at clinical STI testing sites
Home-based self-collection for STI screening has demonstrated high acceptability in clinical studies — removing clinic visit barriers is associated with increased uptake of routine sexual health testing
STI screening is an essential but consistently underused component of sexual health care — confidential at-home testing directly addresses the access and privacy barriers that prevent many individuals from getting screened
Research Basis
STI screening is described by the CDC as an essential and underused component of sexual health assessment in most clinical settings. Combining blood-based HIV screening with NAAT-based bacterial and protozoan detection covers the full spectrum of common STIs in a single testing episode.
CDC STI Risk Assessment Guidelines · NCBI NBK573163 · ClinicalTrials NCT03852316
CLIA-certified Lab
Confidential Results
4 Pathogens
HIPAA Compliant
Secure App Results
FAQ

Frequently Asked Questions

What's included, how to collect, when you'll see results, and how to use them.

What does this panel measure?

This panel screens for the most common sexually transmitted infections, including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and HIV-1 / HIV-2. To ensure accurate detection across different organism types, testing uses two sample types: a finger-prick dried blood spot (DBS) and a self-collected swab (female) or urine sample (male).

How is this different from traditional testing?

Boomerang Kits deliver clinical-grade laboratory accuracy with unmatched discretion and convenience. Samples are collected privately at home, analyzed in a CLIA-certified laboratory, and results are delivered securely through the Boomerang Kits App — without appointments, waiting rooms, or telehealth upsells.

Who benefits most from this panel?

Adults seeking routine, confidential STD screening — including individuals testing after new exposure, between partners, or as part of proactive sexual health monitoring.

What if I have symptoms right now?

If you're experiencing active symptoms or known exposure, seek in-person medical care. This panel is intended for routine screening, not urgent evaluation.

Is this a diagnostic test?

No. This is a laboratory screening panel for informational purposes only. Boomerang Laboratories does not diagnose, treat, or prescribe. Consult a licensed healthcare provider for interpretation and care.

How do I collect my samples?

This panel requires two types of samples:

  • Finger-Prick Blood Sample (DBS) — for HIV screening
  • Self-collected swab (female) or urine sample (male) — for bacterial and protozoal organisms

Follow the step-by-step instructions included in your kit or the Boomerang Kits App. Allow the DBS card to dry fully (approximately 60 minutes) before sealing and returning all samples in the prepaid mailer.

What if my sample can't be processed?

If a sample is insufficient or cannot be analyzed, you'll be notified and sent a complimentary replacement kit.

When will I see my results?

Results are typically available 24–48 hours after the laboratory receives your samples. You'll receive a secure notification when results are ready in the Boomerang Kits App.

Is my data private?

Yes. All testing is performed under strict confidentiality in a CLIA-certified laboratory. Results are encrypted, HIPAA-compliant, and accessible only through your secure app login.

Can I use HSA/FSA funds?

Boomerang Kits are consumer-initiated and not typically billed to insurance. HSA/FSA funds may be used where eligible. Confirm eligibility with your plan provider.

What does this panel measure?

This panel screens for the most common sexually transmitted infections, including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and HIV-1 / HIV-2. To ensure accurate detection across different organism types, testing uses two sample types: a finger-prick dried blood spot (DBS) and a self-collected swab (female) or urine sample (male).

How is this different from traditional testing?

Boomerang Kits deliver clinical-grade laboratory accuracy with unmatched discretion and convenience. Samples are collected privately at home, analyzed in a CLIA-certified laboratory, and results are delivered securely through the Boomerang Kits App — without appointments, waiting rooms, or telehealth upsells.

Who benefits most from this panel?

Adults seeking routine, confidential STD screening — including individuals testing after new exposure, between partners, or as part of proactive sexual health monitoring.

What if I have symptoms right now?

If you're experiencing active symptoms or known exposure, seek in-person medical care. This panel is intended for routine screening, not urgent evaluation.

Is this a diagnostic test?

No. This is a laboratory screening panel for informational purposes only. Boomerang Laboratories does not diagnose, treat, or prescribe. Consult a licensed healthcare provider for interpretation and care.

How do I collect my samples?

This panel requires two types of samples:

  • Finger-Prick Blood Sample (DBS) — for HIV screening
  • Self-collected swab (female) or urine sample (male) — for bacterial and protozoal organisms

Follow the step-by-step instructions included in your kit or the Boomerang Kits App. Allow the DBS card to dry fully (approximately 60 minutes) before sealing and returning all samples in the prepaid mailer.

What if my sample can't be processed?

If a sample is insufficient or cannot be analyzed, you'll be notified and sent a complimentary replacement kit.

When will I see my results?

Results are typically available 24–48 hours after the laboratory receives your samples. You'll receive a secure notification when results are ready in the Boomerang Kits App.

Is my data private?

Yes. All testing is performed under strict confidentiality in a CLIA-certified laboratory. Results are encrypted, HIPAA-compliant, and accessible only through your secure app login.

Can I use HSA/FSA funds?

Boomerang Kits are consumer-initiated and not typically billed to insurance. HSA/FSA funds may be used where eligible. Confirm eligibility with your plan provider.